Beyond Qualified Trials
How Rise achieved 30% higher ROAS on Meta with predictive value signals
Rise already combined high-velocity creative testing with sophisticated optimisation and internal predictive modelling. Day30 built on this foundation with predictive value signals designed for advertising optimisation. In a controlled Meta experiment, the approach delivered 30% higher net D33 ROAS than Rise’s existing Qualified Trial baseline.
+30%
Net D33 ROAS vs Qualified Trial
+23%
Trial-start rate vs Qualified Trial
Controlled A/B Test
Using Meta experiments
All results are relative or indexed, with no absolute spend or revenue disclosed. Net D33 cohort ROAS was measured using consistent MMP last-touch attribution and backend net revenue, after fees and refunds.
Rise

The acquisition challenge
Rise’s Qualified Trial event already offered a more selective indication of customer quality than a conventional trial start.
The opportunity was to go further: could a signal based on predicted revenue help advertising campaigns distinguish not just likely subscribers, but users expected to generate more value?
THE DAY 30 APPROACH
While Qualified Trial identified promising trial behaviour, Day30 used machine learning to estimate differences in expected net customer value.
Those predictions informed an early signal specifically designed for advertising optimisation.
To evaluate the approach fairly, the teams used the same acquisition cohorts and consistent MMP last-touch attribution linked to backend net revenue, rather than relying solely on in-platform ROAS. The predictions also considered refunds when estimating net customer value.
THE PILOT
Rise tested Day30’s approach against its established Qualified Trial optimisation in a controlled Meta experiment.
Creative, budgets and targeting were held consistent, with the optimisation approach as the deliberate variable.
The experiment ran for over a month, with additional time for cohorts to mature to D33 before the final comparison.
The result
Day30 delivered 30% higher net D33 ROAS than Qualified Trial.
The public comparison below is indexed to Rise’s existing baseline:
Optimisation signal
Net D33 ROAS (indexed)
Day30 predictive value signal
130
Rise Qualified Trial
100
Day30’s campaign also achieved a 23% higher trial-start rate and a lower observed refund rate. Although initial acquisition costs were higher, stronger downstream customer value more than offset them, resulting in 30% higher net D33 ROAS.
“We could see the difference in the quality of trials we were acquiring, even with the same creative. Higher conversion rates meant we were reaching more valuable users, giving us confidence to expand the approach into more campaigns.”
Jeff Kahn, Rise
The three pillars



